CBM Daily Digest

FDA Finally Speaks Up!

FDA wants you to know they are still very much here and watching! FDA states their top priority is protecting public health. To that end, it reminds all users that the existence of a product on the shelves does not imply FDA approval or product safety. They also made it clear that aside from false wellness claims, many CBD products are outright mislabeled, contain contaminants, have omitted ingredients, etc.

FDA.gov

We’ve been waiting so long for some FDA guidance on CBD we’ve forgotten that we were waiting. Well friends, get ready to stop waiting! Just kidding, we’re all still waiting. FDA did issue an update on their work related to CBD, their focus on public health, and a little market clarity…however the wait for any form of regulation or dosing information still seems far off.

FDA does want you to know they are still very much here and watching, stating their top priority is protecting public health. To that end, it reminds all users that the existence of a product on the shelves does not imply FDA approval or product safety. They also made it clear that aside from false wellness claims, many CBD products are outright mislabeled, contain contaminants, have omitted ingredients, etc.

The update goes as far as saying FDA is “currently evaluating issuance of a risk-based enforcement policy that would provide greater transparency and clarity regarding factors the agency intends to take into account in prioritizing enforcement decisions.” The update does not say when or provide any other details of this potential enforcement policy.

FDA also wants data, and the largest part of the update was a call for scientists to start researching it. Including collaborating with several other federal agencies, it seems that FDA is recognizing in a serious way just how much data they need to make an informed decision, and just how much they don’t have currently.

Read: FDA.gov statement 3/5/2020

To Top